S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:ORGO

Organogenesis - ORGO Stock Forecast, Price & News

$3.24
-0.01 (-0.31%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.23
$3.43
50-Day Range
$3.14
$6.43
52-Week Range
$3.08
$14.34
Volume
677,421 shs
Average Volume
1.36 million shs
Market Capitalization
$424.08 million
P/E Ratio
5.89
Dividend Yield
N/A
Price Target
$16.50

Organogenesis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
409.3% Upside
$16.50 Price Target
Short Interest
Bearish
10.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.57mentions of Organogenesis in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$14,250 Bought Last Quarter
Proj. Earnings Growth
22.73%
From $0.22 to $0.27 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

55th out of 1,095 stocks

Pharmaceutical Preparations Industry

12th out of 547 stocks

ORGO stock logo

About Organogenesis (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGO Stock News Headlines

Why Organogenesis Stock Is Tumbling Today
See More Headlines
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGO Company Calendar

Last Earnings
8/09/2022
Today
10/02/2022
Next Earnings (Confirmed)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORGO
Fax
N/A
Employees
950
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+409.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$94.90 million
Pretax Margin
9.48%

Debt

Sales & Book Value

Annual Sales
$468.06 million
Cash Flow
$0.91 per share
Book Value
$1.88 per share

Miscellaneous

Free Float
85,863,000
Market Cap
$424.08 million
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Mr. Gary S. Gillheeney Sr.Mr. Gary S. Gillheeney Sr. (Age 67)
    Pres, CEO & Director
    Comp: $1.61M
  • Mr. David C. Francisco (Age 56)
    Chief Financial Officer
    Comp: $553.19k
  • Mr. Patrick Bilbo (Age 60)
    Chief Operating Officer
    Comp: $741.46k
  • Ms. Lori H. Freedman B.A. (Age 55)
    Esq., J.D., VP & Gen. Counsel
  • Mr. Kurt Matheson
    VP of Marketing
  • Mr. Thomas L. Pearl
    VP of HR
  • Dr. Zorina Pitkin
    Sr. VP of Quality Systems
  • Mr. Brian Grow (Age 46)
    Chief Commercial Officer
  • Mr. Henry Hagopian III (Age 54)
    Sr. VP of Fin. & Treasurer
  • Mr. William R. Kolb CPA
    Sec.













ORGO Stock - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ORGO shares.
View ORGO analyst ratings
or view top-rated stocks.

What is Organogenesis' stock price forecast for 2022?

3 equities research analysts have issued 12-month price objectives for Organogenesis' shares. Their ORGO share price forecasts range from $13.00 to $20.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 409.3% from the stock's current price.
View analysts price targets for ORGO
or view top-rated stocks among Wall Street analysts.

How have ORGO shares performed in 2022?

Organogenesis' stock was trading at $9.24 on January 1st, 2022. Since then, ORGO shares have decreased by 64.9% and is now trading at $3.24.
View the best growth stocks for 2022 here
.

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ORGO earnings forecast
.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Wednesday, November 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) issued its quarterly earnings results on Tuesday, August, 9th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.01. The firm earned $121.40 million during the quarter, compared to the consensus estimate of $121 million. Organogenesis had a trailing twelve-month return on equity of 34.04% and a net margin of 15.83%.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $465.00 million-$490.00 million, compared to the consensus revenue estimate of $494.15 million.

What other stocks do shareholders of Organogenesis own?
What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $3.24.

How much money does Organogenesis make?

Organogenesis (NASDAQ:ORGO) has a market capitalization of $424.08 million and generates $468.06 million in revenue each year. The company earns $94.90 million in net income (profit) each year or $0.55 on an earnings per share basis.

How many employees does Organogenesis have?

The company employs 950 workers across the globe.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The official website for the company is organogenesis.com. The company can be reached via phone at (781) 575-0775 or via email at organoir@westwicke.com.

This page (NASDAQ:ORGO) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.